Internal Reference Number: FOI_7816
Date Request Received: 12/03/2024 00:00:00
Date Request Replied To: 09/04/2024 00:00:00
This response was sent via: By Email
Request Summary: Oncology Supplemental
Request Category: Researcher
| Question Number 1: How many patients were treated in the past 3 months for gastric and gastro-oesophageal junction cancer (any stage) with: • FOLFOX (Folinic acid, Fluorouracil and Oxaliplatin) • Lonsurf (Trifluridine - tipiracil) • Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine) • Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine) • Any other systemic anti-cancer therapy • Palliative care only | |
| Answer To Question 1: • FOLFOX (Folinic acid, Fluorouracil and Oxaliplatin) 0 patients • Lonsurf (Trifluridine - tipiracil) 0 patients • Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine) <5 patients • Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine) 0 patients • Any other systemic anti-cancer therapy 5 patients • Palliative care only - unable to answer | |
| Question Number 2: How many early-stage (non-metastatic or Stages 1-3) non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with: • Atezolizumab (Tecentriq) • Durvalumab (Imfinzi) • Nivolumab (Opdivo) • Pembrolizumab (Keytruda) • Chemotherapy • Radiotherapy • Chemotherapy AND Radiotherapy | |
| Answer To Question 2: • Atezolizumab (Tecentriq) <5 patients • Durvalumab (Imfinzi) <5 patients • Nivolumab (Opdivo) <5 patients • Pembrolizumab (Keytruda) <5 patients • Chemotherapy 7 patients • Radiotherapy - Radiotherapy not delivered at SFT. Unable to answer • Chemotherapy AND Radiotherapy - Radiotherapy not delivered at SFT. Unable to answer | |
| Question Number 3: In the past three months, how many advanced renal cell carcinoma patients received the following first-line treatments: • Avelumab + Axitinib (Bavencio + Inlyta) • Cabozantinib (Cometriq) • Nivolumab (Opdivo) • Nivolumab + Cabozantinib (Opdivo + Cometriq) • Nivolumab + Ipilimumab (Opdivo + Yervoy) • Pembrolizumab + Lenvatinib (Keytruda + Kisplyx) | |
| Answer To Question 3: 0 Patients treated. Renal cancer patients are not treated at Salisbury Hospital | |
| To return to the list of all the FOI requests please click here |
Our staff at SA¹ú¼Ê´«Ã½ Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
